Progress of CDK4/6 inhibitors in the treatment of malignant tumors

Progress of CDK4/6 inhibitors in the treatment of malignant tumors

CDK4/6 inhibitor acts on cell cycle. It can be used alone or in combination to treat lung cancer, liver cancer, pancreatic cancer and other cancers by restoring normal cell cycle, triggering antitumor immunity and changing the microenvironment of tumors. It has a certain therapeutic effect, and h...

Full description

Bibliographic Details
Main Authors:	Bin Fu, Zhen Rong
Format:	Article
Language:	English
Published:	Editorial Board of Journal of Hainan Medical University 2019-11-01
Series:	Journal of Hainan Medical University
Subjects:	cdk4/6 inhibitor molecular targeted drug cancer treatment lung cancer breast cancer
Online Access:	http://www.hnykdxxb.com/PDF/201911/16.pdf

Similar Items

Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer
by: Wu Y, et al.
Published: (2020-05-01)

Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer
by: Navid Sobhani, et al.
Published: (2021-02-01)

CDK4/6 inhibitors in advanced breast cancer, what is beyond?
by: Amrallah A. Mohammed, et al.
Published: (2019-07-01)

CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience
by: Angeliki Andrikopoulou, et al.
Published: (2021-06-01)

LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer
by: Xi Jin, et al.
Published: (2020-05-01)

Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review
by: Angeliki Andrikopoulou, et al.
Published: (2021-01-01)

CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge
by: Debora de Melo Gagliato, et al.
Published: (2020-09-01)

Recent advances of highly selective CDK4/6 inhibitors in breast cancer
by: Hanxiao Xu, et al.
Published: (2017-04-01)

MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment
by: Angeliki Andrikopoulou, et al.
Published: (2021-08-01)

Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience
by: Michela Palleschi, et al.
Published: (2020-08-01)

Personalized Medicine and Biomarker Discovery to Targeted Therapies in Breast Cancer : Focus on CDK4/6 Inhibitors
by: Arnedos Ballester, Monica
Published: (2019)

The Pharmacological Profile of Cyclin-dependent Kinase (CDK) 4/6 Inhibitors: Clinical Management of Toxicity and Drug Interactions Related to CDK 4/6 Inhibitor-based Treatment in Advanced/Metastatic Breast Cancer
by: Vasiliki Tzelepi C., et al.
Published: (2020-04-01)

SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors
by: Flora Zagouri, et al.
Published: (2021-12-01)

Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
by: Michela Piezzo, et al.
Published: (2020-09-01)

Role of CDK4/CDK6 inhibitors: Ribociclib, Palbocilcib and Abemacilcib in treatment of metastatic breast cancer
by: Ghobadpour, Nazanin
Published: (2021)

Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
by: Michela Piezzo, et al.
Published: (2020-09-01)

Assessment of Resistance Mechanisms and Clinical Implications in Patients with KRAS Mutated-Metastatic Breast Cancer and Resistance to CDK4/6 Inhibitors
by: Lucrezia Raimondi, et al.
Published: (2021-04-01)

Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial
by: A. van Ommen-Nijhof, et al.
Published: (2018-11-01)

A Protracted Course of COVID19 Infection in a Metastatic Breast Cancer Patient During CDK4/6 Inhibitor Therapy
by: Albert Grinshpun, et al.
Published: (2020-06-01)

Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer
by: Xiuzhi Zhu, et al.
Published: (2021-04-01)

Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
by: Zhen Li, et al.
Published: (2020-11-01)

Research Progress of CDK4/6 Inhibitors in Non-small Cell Lung Cancer
by: Qiong QIN, et al.
Published: (2020-03-01)

Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
by: Ilenia Migliaccio, et al.
Published: (2021-05-01)

CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
by: Yilan Yang, et al.
Published: (2020-09-01)

Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors
by: Roman V. Uzhachenko, et al.
Published: (2021-04-01)

Advances in Therapy for Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer Patients Who Have Experienced Progression After Treatment with CDK4/6 Inhibitors
by: Li C, et al.
Published: (2021-05-01)

CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives
by: Michela Roberto, et al.
Published: (2021-01-01)

Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
by: Mridula A. George, et al.
Published: (2021-07-01)

Highlights of the Latest Advances in Research on CDK Inhibitors
by: Jonas Cicenas, et al.
Published: (2014-10-01)

Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms
by: Bin Wang, et al.
Published: (2021-05-01)

Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience
by: Irina V. Kolyadina, et al.
Published: (2020-07-01)

The place of CDK4/6 inhibitors in real clinical practice for patients with hormone-positive HER2-negative advanced breast cancer: opinion of Moscow’s oncologists
by: L. G. Zhukova, et al.
Published: (2020-06-01)

H2AFZ: A Novel Prognostic Marker in Canine Melanoma and a Predictive Marker for Resistance to CDK4/6 Inhibitor Treatment
by: Laura Bongiovanni, et al.
Published: (2021-08-01)

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
by: Kamal Pandey, et al.
Published: (2020-11-01)

CDK4/6 inhibitors in the treatment of metastatic breast cancer. Choosing optimal therapy for estrogen-receptor-positive HER2-negative metastatic breast cancer: analysis of doctors’ preferences (“Prometheus”) in Russia – first results of the survey
by: E. V. Artamonova, et al.
Published: (2021-01-01)

Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials
by: Hong-Fei Gao, et al.
Published: (2021-10-01)

Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers
by: Suryavathi Viswanadhapalli, et al.
Published: (2019-12-01)

Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer
by: Knudsen, Erik S., et al.
Published: (2014)

Performance of protein-ligand docking with CDK4/6 inhibitors: a case study
by: Linlu Song, et al.
Published: (2021-04-01)

The application and prospect of CDK4/6 inhibitors in malignant solid tumors
by: Qi Du, et al.
Published: (2020-05-01)